Drugs

PEER-REVIEWED FEATURE

Lutetium LU 177 Vipivotide Tetraxetan: Adis Evaluation

Key Points

- A radioligand therapeutic agent (a radiopharmaceutical) being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of PSMA-positive metastatic prostate cancer
- Received its first approval on 23 March 2022 in the USA
- Approved for use in adult patients with PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy

Summary

Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer.

The active part of the radiopharmaceutical is lutetium-177, which is linked to a ligand that binds to prostate-specific membrane antigen (PSMA), a transmembrane enzyme overexpressed in primary and metastatic prostate cancers.

Based on efficacy results from the phase 3 VISION trial, lutetium Lu 177 vipivotide tetraxetan was approved in the USA on 23 March 2022 for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Regulatory review in the EU and other countries is underway.

Keam. S.J. 2022. https://doi.org/10.1007/s40291-022-00594-2